Renally clearable ytterbium nanoparticle contrast agents for spectral photon counting computed tomography

项目总结 传统的CT成像在现代医学中应用非常广泛，每年进行8000万次扫描 美国。CT具有重要的心血管应用，如钙化评分和冠状动脉 血管造影术。一种新的CT形式正在出现，它被称为光谱光子计数CT(SPCCT)。这 与传统CT中使用的能量积分探测器不同，CT使用光子计数探测器 CT.SPCCT承诺改进常规CT，如更低的辐射剂量，更高的空间 分辨率和改进的区分材料的能力。目前使用的碘基造影剂用于 CT成像有几个缺点，如清除非常快，缺乏疾病靶向性，过敏反应 和潜在的肾脏损害，特别是对SPCCT来说不是理想的，因为它很难成像 具体地说。因此，需要开发为SPCCT设计的新造影剂，其能够提供 更准确和增强的心血管疾病诊断。我们发现，Yb是最多的 产生SPCCT对比度的有效元素。我们将开发新的、高度生物兼容的Yb3+ 用于SPCCT高精度和低剂量心血管成像的纳米造影剂。

PROJECT SUMMARY Conventional CT imaging is very widely used in modern medicine, with 80 million scans performed per year in the USA. CT has important cardiovascular applications such as calcium scoring and coronary artery angiography. A new form of CT is emerging, which is known as spectral photon counting CT (SPCCT). This type of CT uses photon counting detectors as opposed to the energy integrating detectors used in conventional CT. SPCCT promises improvements over conventional CT such as lower radiation dose, higher spatial resolution and an improved ability to distinguish materials. The current iodine-based contrast agents used in CT imaging have several deficiencies such as very rapid clearance, lack of disease targeting, allergic reactions and potential for kidney damage, and are not ideal for SPCCT in particular since it is difficult to image iodine specifically. There is a need, therefore, to develop new contrast agents designed for SPCCT that can provide more accurate and enhanced diagnoses for cardiovascular disease. We have found that ytterbium is the most potent element for SPCCT contrast generation. We will develop novel, highly biocompatible ytterbium nanoparticle contrast agents for highly precise and low dose cardiovascular imaging with SPCCT.